Here, first experiences with a prototype tool for high throughput (passive) permeability profiling, a 96-well plate comprising the Permeapad® membrane, are reported. The permeabilities of a set of drugs were determined and compared to published measures of oral absorption, such as human fraction absorbed (Fa) and in vitro permeability values obtained using other tools.
The tool consists of a 96-well bottom and screen plate with the artificial, phospholipid-based barrier (Permeapad®) mounted between the plates’ lower and upper compartments. The permeability of 14 model compounds including high- and low-absorption drugs, cationic, anionic, zwitterionic and neutral molecules, was determined by quantifying the compounds’ transport over time, deriving the steady-state flux from the linear part of the cumulative curves and calculating the apparent permeability (Papp). The membrane structure was investigated in a high-resolution digital light microscope.
The Permeapad® 96-well plate was found suited to distinguish high and low absorption drugs and yielded a hyperbolic correlation to Fa. The Papp values obtained were congruent with those determined with in-house prepared Permeapad® in the Franz cell set-up. Furthermore, good to excellent correlations were seen with Caco-2 permeability (R2 = 0.70) and PAMPA permeability (R2 = 0.89). Microscopic investigation of the Permeapad® barrier revealed the formation of phospholipid vesicles and myelin figures in aqueous environment.
The Permeapad® 96-well plate permeation set-up is a promising new tool for rapid and reproducible passive permeability profiling.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
- Fa :
Fraction absorbed in humans
High-performance liquid chromatography
Parallel artificial membrane permeability assay
- Papp :
Phosphate buffered saline
Phospholipid vesicle-based permeation assay
Total polar surface area
Ultra-high-performance liquid chromatography with ultraviolet detection
Unstirred water layer
Sugano K, Kansy M, Artursson P, Avdeef A, Bendels S, Di L, et al. Coexistence of passive and carrier-mediated processes in drug transport. Nat Rev Drug Discov. 2010;9:597–614.
Berben P, Bauer-Brandl A, Brandl M, Faller B, Flaten GE, Jacobsen A-C, et al. Drug permeability profiling using cell-free permeation tools: overview and applications. Eur J Pharm Sci. 2018;119:219–33.
Kansy M, Senner F, Gubernator K. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J Med Chem American Chemical Society. 1998;41:1007–10.
Teksin ZS, Seo PR, Polli JE. Comparison of drug Permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J. 2010;12:238–41.
Avdeef A, Artursson P, Neuhoff S, Lazorova L, Gråsjö J, Tavelin S. Caco-2 permeability of weakly basic drugs predicted with the double-sink PAMPA pKaflux method. Eur J Pharm Sci. 2005;24:333–49.
Flaten GE, Dhanikula AB, Luthman K, Brandl M. Drug permeability across a phospholipid vesicle based barrier: a novel approach for studying passive diffusion. Eur J Pharm Sci. 2006;27:80–90.
di Cagno M, Bibi HA, Bauer-Brandl A. New biomimetic barrier Permeapad™ for efficient investigation of passive permeability of drugs. Eur J Pharm Sci. 2015;73:29–34.
Lasic DD. Structure of amphiphilic aggregates. In: D.D. Lasic, editor. Liposomes from Phys to Appl. Elsevier Amsterdam; 1993. p. 43–62.
Volkova T V, Terekhova I V, Silyukov OI, Proshin AN, Bauer-Brandl A, Perlovich GL. Towards the rational design of novel drugs based on solubility, partitioning/distribution, biomimetic permeability and biological activity exemplified by 1,2,4-thiadiazole derivatives. Medchemcomm. The Royal Society of Chemistry; 2017;8:162–175.
Bibi HA, di Cagno M, Holm R, Bauer-Brandl A. Permeapad™ for investigation of passive drug permeability: the effect of surfactants, co-solvents and simulated intestinal fluids (FaSSIF and FeSSIF). Int J Pharm. 2015;493:192–7.
Volkova TV, Domanina EN, Kumeev RS, Proshin AN, Terekhova IV. The effect of different polymers on the solubility, permeability and distribution of poor soluble 1,2,4-thiadiazole derivative. J Mol Liq. 2018;269:492–500.
Bibi HA, Holm R, Bauer-Brandl A. Simultaneous lipolysis/permeation in vitro model, for the estimation of bioavailability of lipid based drug delivery systems. Eur J Pharm Biopharm. 2017;117:300–7.
Fong SYK, Martins SM, Brandl M, Bauer-Brandl A. Solid phospholipid dispersions for Oral delivery of poorly soluble drugs: investigation into Celecoxib incorporation and solubility-in vitro permeability enhancement. J Pharm Sci. 2016;105:1113–23.
Jacobsen A-C, Elvang PA, Bauer-Brandl A, Brandl M. A dynamic in vitro permeation study on solid mono- and diacyl-phospholipid dispersions of celecoxib. Eur J Pharm Sci. 2019;127:199–207.
Wu IY, Bala S, Škalko-Basnet N, di Cagno MP. Interpreting non-linear drug diffusion data: Utilizing Korsmeyer-Peppas model to study drug release from liposomes. Eur J Pharm Sci 2019;138:105026.
Agafonov M, Volkova T, Kumeev R, Chibunova E, Terekhova I. Impact of pluronic F127 on aqueous solubility and membrane permeability of antirheumatic compounds of different structure and polarity. J Mol Liq. 2019;274:770–7.
Volkova T, Kumeev R, Kochkina N, Terekhova I. Impact of Pluronics of different structure on pharmacologically relevant properties of sulfasalazine and methotrexate. J Mol Liq. 2019;289:111076.
Hermanson GT. Chapter 10 - fluorescent probes. In: Hermanson GTBT-BT (third E, editor. Boston: Academic Press; 2013. p. 395–463.
Brandl M, Tardi C, Drechsler M, Bachmann D, Reszka R, Bauer KH, et al. Three-dimensional liposome networks: freeze fracture electron microscopical evaluation of their structure and in vitro analysis of release of hydrophilic markers. Adv Drug Deliv Rev. 1997;24:161–4.
Brandl M. Vesicular phospholipid gels: a technology platform. J Liposome Res Taylor & Francis. 2007;17:15–26.
Sugano K. 5.19 - Artificial Membrane Technologies to Assess Transfer and Permeation of Drugs in Drug Discovery. In: Taylor JB, Triggle DJBT-CMCII, editors. Oxford: Elsevier; 2007. p. 453–487.
Flaten GE, Bunjes H, Luthman K, Brandl M. Drug permeability across a phospholipid vesicle-based barrier: 2. Characterization of barrier structure, storage stability and stability towards pH changes. Eur J Pharm Sci. 2006;28:336–43.
Karlsson J, Artursson P. A method for the determination of cellular permeability coefficients and aqueous boundary layer thickness in monolayers of intestinal epithelial ( Caco-2) cells grown in permeable filter chambers. Int J Pharm. 1991;71:55–64.
Nielsen PE, Avdeef A. PAMPA—a drug absorption in vitro model: 8. Apparent filter porosity and the unstirred water layer. Eur J Pharm Sci. 2004;22:33–41.
Wolk O, Markovic M, Porat D, Fine-Shamir N, Zur M, Beig A, Dahan A. Segmental-dependent intestinal drug permeability: development and model validation of In silico predictions Guided by In Vivo permeability values. J Pharm Sci Elsevier; 2019;108:316–325.
Bibi HA, Holm R, Bauer-Brandl A. Use of Permeapad® for prediction of buccal absorption: a comparison to in vitro, ex vivo and in vivo method. Eur J Pharm Sci. 2016;93:399–404.
Teksin ZS, Hom K, Balakrishnan A, Polli JE. Ion pair-mediated transport of metoprolol across a three lipid-component PAMPA system. J Control Release. 2006;116:50–7.
Zhu C, Jiang L, Chen T-M, Hwang K-K. A comparative study of artificial membrane permeability assay for high throughput profiling of drug absorption potential. Eur J Med Chem. 2002;37:399–407.
Artursson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun. 1991;175:880–5.
Yazdanian M, Glynn SL, Wright JL, Hawi A. Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res. 1998;15:1490–4.
Yamashita S, Furubayashi T, Kataoka M, Sakane T, Sezaki H, Tokuda H. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Eur J Pharm Sci. 2000;10:195–204.
Ghartey-Tagoe EB, Morgan JS, Neish AS, Prausnitz MR. Increased permeability of intestinal epithelial monolayers mediated by electroporation. J Control Release. 2005;103:177–90.
Kogan A, Kesselman E, Danino D, Aserin A, Garti N. Viability and permeability across Caco-2 cells of CBZ solubilized in fully dilutable microemulsions. Colloids Surfaces B Biointerfaces. 2008;66:1–12.
Morrison RA, Chong S, Marino AM, Wasserman MA, Timmins P, Moore VA, et al. Suitability of Enalapril as a probe of the dipeptide transporter system: InVitro and in vivo studies. Pharm Res. 1996;13:1078–82.
Antonescu IE, Rasmussen KF, Neuhoff S, Fretté X, Karlgren M, Bergström CAS, et al. The permeation of Acamprosate is predominantly caused by Paracellular diffusion across Caco-2 cell monolayers: a Paracellular modeling approach. Mol Pharm. American Chemical Society. 2019;16:4636–50.
Pade V, Stavchansky S. Link between drug absorption solubility and permeability measurements in Caco-2 cells. J Pharm Sci Elsevier. 1998;87:1604–7.
Takenaka T, Harada N, Kuze J, Chiba M, Iwao T, Matsunaga T. Application of a human intestinal epithelial cell monolayer to the prediction of Oral drug absorption in humans as a superior alternative to the Caco-2 cell monolayer. J Pharm Sci. 2016;105:915–24.
Yee S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man—fact or myth. Pharm Res. 1997;14:763–6.
Zur M, Gasparini M, Wolk O, Amidon GL, Dahan A. The low/high BCS permeability class boundary: physicochemical comparison of Metoprolol and labetalol. Mol Pharm American Chemical Society. 2014;11:1707–14.
Vertzoni M, Augustijns P, Grimm M, Koziolek M, Lemmens G, Parrott N, et al. Impact of regional differences along the gastrointestinal tract of healthy adults on oral drug absorption: an UNGAP review. Eur J Pharm Sci. 2019;134:153–75.
Lüpfert C, Reichel A. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery. Chem Biodivers. John Wiley & Sons, Ltd; 2005;2:1462–86.
The sponsor has not taken any influence on study design, data interpretation or writing of the current manuscript.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Jacobsen, AC., Nielsen, S., Brandl, M. et al. Drug Permeability Profiling Using the Novel Permeapad® 96-Well Plate. Pharm Res 37, 93 (2020). https://doi.org/10.1007/s11095-020-02807-x
- 96-well plate
- artificial barrier
- high throughput
- intestinal absorption